Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial - Mease,P.J.; Gladman,D.D.; Ritchlin,C.T. (Arthritis Rheum, 2005)